The phase I/II study of the adjuvant therapy using alpha-galactosylceramide pulsed dendritic cells for patients with advanced high-grade salivary gland tumor followed by standard therpies.
Not Applicable
- Conditions
- Salivary gland tumor
- Registration Number
- JPRN-UMIN000024669
- Lead Sponsor
- Chiba University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
1) Past history of hepatitis. 2) A positive response for HBs antigen/HCV antibody/HIV antibody/HTL-V1 antibody. 3) Concurrent corticosteroid therapy. 4) Pregnancy or lactation. 5) Autoimmune disease. 6) Sever infection 7) Uncontrolled DM. 8) Sever pulmonary emphysema or fibrosis. 9) Serious cardiac disease. 10) Double cancer. 11) Hypersensitivity for albumin 12) Judgement of physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase I: Safety profile Phase II: Two-year overall survival
- Secondary Outcome Measures
Name Time Method Evaluation of peripheral iNKT cell specific immune response